Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since exogenous surfactant replacement therapy was first used to prevent neonatal respiratory distress syndrome (NRDS)，it has become the main method of treatment of NRDS. However, in some infants, death is inevitable despite intensive care and surfactant replacement therapy, especially in near-term and term infants. The first goal of our study is to compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS. The second goal of our study is to further analyze the risk factors and causes of RDS in early preterm infants and near term/term infants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| early preterm infants with RDS | gestational age<34 weeks |
| |
| near term infants with RDS | 34 weeks≤gestational age< 37 weeks |
| |
| term infants with RDS | Gestational age ≥ 37 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surfactant, Pulmonary，Curosurf | Drug | All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS. |
| Measure | Description | Time Frame |
|---|---|---|
| therapeutic effect of pulmonary surfactant of infants at different gestational ages | January 1，2011 to December 30，2016 |
Not provided
Not provided
Inclusion Criteria:
Infants with RDS who received surfactant therapy were recruited between January 2011 and December 2016.
Exclusion Criteria:
Infants were excluded if they had any congeni- tal malformation, inherited metabolic abnormality, intrauterine infection, Rh/Rh incompatibility, pneumonia, pulmonary hypertension, meconium aspiration syndrome, or asphyxia.
Not provided
Not provided
Infants with RDS who received surfactant therapy were recruited from 24 hospitals between January 2011 and December 2016.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Li Wang, Doctor | Contact | 008613527499258 | liwang8771@126.com | |
| Yuan Shi, Doctor | Contact | 13527499258@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Li Wang, Doctor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of pediatrics, Daping Hospital, The Third Military Medical University | Recruiting | Chongqing | Chongqing Municipality | 400042 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013501 | Surface-Active Agents |
| ID | Term |
|---|---|
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Perinatal risk factors of NRDS | Other | Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS. |
|